ContextVision has made significant investments in artificial intelligence technology over the last decade. Today we have a R&D team with extensive experience and knowledge in the field, and we launched our first AI-based product in 2018.
Today we train machines to recognize objects (in this case, faces) by feeding a range of images into a deep network, which then predicts an output (in this case, a name). The output of the network is compared with the correct answer and a feedback signal updates the weights in the network until predictions are sufficiently correct.
Our deep learning skills have been confirmed by top rankings in several international competitions. Since then, we have focused on using our skills to develop innovative products within medical imaging and digital pathology.
Altumira™ / Altumira™ Plus
Altumira is ContextVision’s first AI-based product, and our latest generation of image enhancement for static and dynamic digital X-ray. Altumira is a combination of our world leading technology and powerful machine learning algorithms. The algorithms are used to address the challenges of producing robust and harmonized image quality, both within image sequences and in images from different patients. In Altumira, the machine learning algorithm analyzes the image and controls the image processing parameters to optimize the output of the image enhancement.
Harmonized intensity levels/brightness stabilization in dynamic sequence handling large variations in e.g. dose, intensity levels, and field-of-view.
Processed with Altumira™ Plus
INIFY Prostate Screening
INIFY® Prostate Screening provides pathologists with a decision support tool that explores the advantages of new digital technology in whole new ways. Drawing on the very latest breakthroughs in deep learning, INIFY Prostate Screening empowers pathologists faced with today’s ever-increasing workload. It makes room for smarter, more accurate and faster decisions, and is already proven to be adaptable to different workflows and user needs. INIFY Prostate Screening builds on the strong foundation of innovation, technical know-how and professionalism that has been a trademark of ContextVision for the last 30 years.
Power to the pathologist!
INIFY® is a registered trademark of ContextVision AB
Grand Challenge TUPAC 16 (TUmour Proliferation Assessment Challenge) finds mitoses in breast tissue and predicts the proliferation score (which relates to aggressiveness of the cancer)
True and false positive mitoses are often hard to separate.
Real time 3D (“4D”) enhanced ultrasound “smiling” fetus, and a photo of the same “smiling” baby after birth.
ContextVision’s own history allows us to take such a leap into deep learning. Our GOP technology – used within the company for over 30 years – has many similarities to neural networks, as it is also inspired by the human visual system. Networks of convolutions are included in many of our products for 2D/3D/4D enhancement today. The learning parts of these networks (i.e. artificial intelligence) are new. ContextVision has also established processes for effective product development and implementations on different platforms, and has extensive knowledge in these areas.
With the new AI technology, we can develop machines to help humans, resulting in better treatment and more effective healthcare.